CliffBio
small molecule

COMBIGAN

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCOMBIGAN
Active ingredientBRIMONIDINE TARTRATE; TIMOLOL MALEATE
Strength0.2%;EQ 0.5% BASE
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalOctober 2007
Marketing statusRX

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

COMBIGAN patent cliff — loss of exclusivity — | CliffBio